Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XNK03
- Development stage
- Preclinical
- Lead developer
- XNK Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
XNK03 is an autologous natural killer (NK) cell therapy candidate being developed by XNK Therapeutics for the treatment of urothelial malignancies, particularly bladder cancer. It is produced using XNK’s proprietary closed-system platform, which selectively expands and activates NK cells from a patient’s own peripheral blood to enhance cytotoxic activity against tumor cells. XNK03 is in preclinical evaluation, including studies in collaboration with Karolinska University Hospital in patients with locally advanced or metastatic urothelial cancer, where patient-derived cells collected before and after chemotherapy are used to test and optimize NK cell–mediated killing of autologous tumor cells.
Beyond the preview
Go deeper on XNK03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XNK03.